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Intravesical instillation of Bacillus Calmette-Gue ´rin (BCG) is used for the treatment of superficial bladder cancer, both to reduce the
recurrence rate of bladder tumour and to diminish the risk of progression. Since its first therapeutic application in 1976, major
research efforts have been directed to decipher the exact mechanism of action of the BCG-associated antitumour effect. Bacillus
Calmette-Gue ´rin causes an extensive local inflammatory reaction in the bladder wall. Of this, the massive appearance of cytokines in
the urine of BCG-treated patients stands out. Activated lymphocytes and macrophages are the most likely sources of these cytokines,
but at present other cellular sources such as urothelial tumour cells cannot be ruled out. Bacillus Calmette-Gue ´rin is internalised and
processed both by professional antigen-presenting cells and urothelial tumour cells, resulting in an altered gene expression of these
cells that accumulates in the presentation of BCG antigens and secretion of particular cytokines.
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Bladder cancer is detected in 75% of patients at an early,
superficial stage. The majority of the superficial urothelial cell
carcinomas (TCCs) consists of papillary bladder carcinomas
(Figure 1A), while the remaining (10%) is called carcinoma in
situ (CIS), a high-grade diffuse surface-spreading lesions. The
standard treatment is trans-urethral resection (TUR) followed by
intravesical instillation with adjuvant, chemo- or immunother-
apeutic drugs (Kurth et al, 2000). For treatment of the surgically
nonaccessible CIS, these latter modalities are the only bladder
sparing options available. Although the therapeutic efficacy is well
recognised, a high recurrence rate of 60–70% and a progression
rate of 15% dictate the need for lifelong follow-up and treatment.
Adjuvant agents were introduced to reduce the risk for
recurrence and progression of TCC. Recent, comparative trials
indicate that immunotherapy with Bacillus Calmette-Gue ´rin (BCG;
Figure 1B) is superior to chemotherapy in patients with
intermediate to high risk for recurrence. In these patients, the
benefits of treatment outweigh the burden of side effects.
Moreover, BCG seems to exert a better antitumour effect in CIS
and high-grade cancer (Melekos et al, 1993; Kurth et al, 2000).
Bacillus Calmette-Gue ´rin, an attenuated strain of Mycobacter-
ium bovis, was developed by Calmette and Gue ´rin with the
intention to generate a vaccine against tuberculosis. The clinical
efficacy of the commercially available strains of BCG, such as
Connaught and Tice, appears to be comparable (Witjes et al, 1996;
Champetier et al, 2000).
Since the first report of intravesical use of BCG in 1976,
investigators try to understand the working mechanism of BCG as
an antitumour modality. Both BCG treatment regimen and dose
are historically determined. Arbitrarily, BCG therapy consists of a
single course of six weekly intravesical instillations. Extension of
BCG treatment (maintenance immunotherapy) is used to increase
efficacy. Despite its success, 30–50% of patients either fail to
respond or relapse within the first 5 years of treatment.
Unfortunately, BCG, a viable, living organism, can cause infections
resulting in side effects ranging from bothersome cystitis in the
majority of patients to sepsis eventually leading to death in rare
cases.
In order to reduce the side effects of BCG and to improve
efficacy, interesting approaches are developed, such as the
application of a cell wall–DNA complex (MCC) of Mycobacterium
phlei, which was effective in patients who failed BCG therapy
(Morales et al, 2001), genetically engineered BCG secreting
relevant cytokines such as human lL-2 (Yamada et al, 2000), or
treatment schedules consisting of three times viable BCG and three
subsequent instillations with killed BCG (De Boer et al, 2003).
This review presents an overview of the current state of ‘BCG
research’. Special attention will be paid to the role of the urothelial
cells in the cascade of events leading to BCG-associated tumour
cell clearance. As an underdeveloped field of research, the
significance of an interaction between potentially hostile bacteria
and epithelial cells is a relatively unknown aspect of the host
immune-defense system. Better knowledge about this interaction
might open new avenues for improvement of the BCG immu-
notherapy.
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immunotherapy for TCC with BCG, the reader is referred to
various, recently published papers (Kurth et al, 2000).
DETAILS OF THE MODE OF ACTION OF BCG
Nowadays, it is generally assumed that the BCG-induced
antitumour activity is critically dominated by a local nonspecific
immunological reaction reflecting the activity of immunocompe-
tent cells (Alexandroff et al, 1999). It should be realised however
that preceding the activation of the local immune system, some
possibly rate-limiting events need to be executed. The sequential
order of these initial events has been addressed only to a limited
extent.
Interaction of BCG with the bladder wall
Interaction of BCG with the luminal surface of the bladder is the
first step for BCG to accomplish. Accumulation of BCG near the
bladder wall and adherence may be limiting processes for an
adequate, clinical response. Suboptimal binding of BCG may
explain the absence of clinical response in a subgroup of patients
(Ratliff et al, 1987; Schamhart et al, 1994). Experimental
modulation of BCG attachment affects BCG-induced response in
animal models (Hudson et al, 1991). Systematic analysis of the
interaction of BCG with the bladder wall has not been
accomplished, probably due to poor recognition of the biological
and physicochemical processes involved. The process of interac-
tion should be divided into nonspecific, physicochemical and
specific, receptor–ligand-mediated events.
Physicochemical interaction The luminal side of the bladder is
covered with a layer of hydrophilic, highly sulphated glycosami-
noglycans (GAGs). This GAG layer protects the bladder from toxic
compounds and microorganisms. Both the GAG layer and the BCG
cell wall are highly negatively charged (the zeta potentials). These
conditions prescribe that BCG bacteria accumulate without
adherence, at a close docking distance (70–100A ˚) to the bladder
wall (Figure 1C) (Schamhart et al, 1994). In addition to this
reversible adsorption, physicochemical considerations predict a
low probability of irreversible adherence of BCG to the bladder
wall, due to the high electrostatic, repellent force between the
respective surfaces. The observed, in animals, low abundance of
BCG adherence to the uninjured bladder wall and the dependency
of BCG adherence to diluent properties (pH, salt concentration)
seem to be in accord with these theoretical considerations (Ratliff
et al, 1987; Hudson et al, 1991; Teppema et al, 1992). Damage of
the GAG layer and urothelium may lower the negative charge of
the bladder wall, leading to an increased BCG docking and
adherence, as observed in a murine BCG model after electrocautery
damage of the bladder (Ratliff et al, 1987).
Specific, receptor–ligand-mediated events In addition to non-
specific interaction, more specific mechanisms seem to be involved
in BCG adherence. A crucial binding of BCG to fibronectin (FN) in
the bladder mucosa has been postulated (Kavoussi et al, 1990).
Fibronectin is part of the extracellular matrix, is equally
distributed on normal and malignant urothelium, and a soluble
form can be found in urine. Binding of BCG to the murine bladder
was impaired with anti-FN antibodies or addition of soluble FN
(Kavoussi et al, 1990). Furthermore, BCG bacteria possess a
receptor with high affinity for the collagen domain of FN, the
fibronectin attachment protein (FAP). These data and the
observation that the clinical effect of BCG therapy is related to
the degree of FN expression on normal mucosa suggest a specific
FN-mediated adherence of BCG to the bladder wall. However, these
experimental, animal data were largely obtained with preinjured
bladders, contradictory to the clinical situation, and a fortuitous
relationship between the efficacy of BCG therapy and fibronectin
has been suggested (Bevers et al, 1998, 2000).
Internalisation of BCG and phenotypical alterations of
urothelial cells
Internalisation of BCG in urothelial cells Several reports show
that urothelial cells are capable of internalisation of BCG (Bevers
et al, 1998, 2000; Durek et al, 1999). Bacillus Calmette-Gue ´rin
internalisation in vitro is time and dose dependent and can already
be demonstrated after a 15-min incubation period. In a spheroid 3-
D model, internalised BCG was found four cell layers deep,
whereas normal urothelial cells in this system did not internalise
BCG (Durek et al, 1999). Guinea pig studies showed no adherent or
internalised BCG in normal urothelial cells (Teppema et al, 1992).
In malignant cells, BCG internalisation appeared to be cell
differentiation dependent. Contrary to well-differentiated (G1)
bladder tumour cell lines, poorly differentiated (G3) cell lines
exhibit significant internalisation of BCG (Bevers et al, 1998).
Clinically, these data relate well to observations that show a better
response to BCG treatment of high-grade compared to low-grade
tumours (Table 1) (Melekos et al, 1993).
Knowledge about the mechanism of BCG internalisation is
scarce. Fibronectin is suggested to act as a bridging molecule,
binding both to urothelial cells and BCG. Urothelial cells express
an integrin (a5b1 receptor) with affinity for FN (Zhao et al, 2000).
Pretreatment of T24 cells, a human TCC cell line, with anti-FN or
anti-a5b1-receptor antibodies resulted in an impaired BCG
attachment to and internalisation in these cells. However, other
investigators could not inhibit BCG internalisation with anti-FN
antibodies (Schneider et al, 1994; Bevers et al, 2000). The current
available data do not suggest a mandatory role of FN in BCG
internalisation. It seems that BCG internalisation is mediated by
additional molecule(s), possibly coexpressed with FN, such as
heparan sulphate-containing proteoglycans interacting with the
mycobacterial heparin-binding haemagglutinin adhesin (HBHA)
(Schneider et al, 1994; Bevers et al, 2000).
Regardless of the exact mechanism of internalisation, intracel-
lular BCG is transported within phagosomes. These fuse with
lysosomes to form phagolysosomes. Recent evidence shows that
intracellular, live BCG can interfere with this phagolysosome
formation (Maksymowych and Kane, 2000). However, only a small
fraction of commercially available BCG preparations consists of
live BCG. Therefore, most BCG particles will be degraded, and
mycobacterial glycoproteins and lipoproteins are transported to
the cell surface (Neyrolles et al, 2001).
Patient studies, analysing bladder washings after BCG instilla-
tions, revealed vigorous phagocytosis of BCG by leucocytes.
However, concerning internalised BCG in urothelial cells, conflict-
ing results are reported (Teppema et al, 1992). Accepting the
inability of normal urothelial cells to internalise BCG, these
conflicting observations may be explained by the presence or
absence of residual urinary tumour cells in the limited number of
patients included in both studies.
In summary, BCG particles can be internalised and processed by
residual, especially high-grade tumour cells. As a consequence, the
possibility that BCG introduces phenotypical alterations of TCC
Table 1 Recurrence rate/100 patients-months in patients with superficial
bladder cancer, following TUR with and without adjuvant intravesical BCG
instillations
a
Treatment Grade 1 Grade 2 Grade 3
TUR 1.5 NS 3.67 Po0.01 20.83 Po0.002
TUR+BCG 1.18 1.02 1.26
aData from Melekos et al (1993); NS¼not significant.
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of study. Several effects, ranging from a direct antiproliferative/
cytotoxic effect of BCG, to a role in the initiation and/or
modulation of the host immune response, and to an increase of
susceptibility of tumour cells, have been proposed.
Cytotoxic effects of BCG on BCG-internalising urothelial
cells
In vitro studies with human TCC cell lines show that BCG exerts
cytolytic, antiproliferative and antimotility effects. The inhibitory
effects on cell proliferation were most pronounced in highly
dedifferentiated cell lines. Today, the causal mechanisms are
unknown. Internalised BCG increased the production of cytotoxic
nitric oxide (NO) in TCC cells. Patients treated with BCG showed
an augmented bladder NO production and an upregulation of
urothelial-associated nitric oxide synthase (Jansson et al, 1998).
NO, at high concentration, may cause DNA damage, and cytostatic
and cytotoxic effects. Possible accumulation of DNA damage may
be related to the observation that, contrary to nontreated patients,
urothelial cells of BCG-treated patients express regulatory genes
related to DNA repair, knowingly wild-type p53 and P21
waf1/cip1
(Fontana et al, 1999). Whether these observations represent an
indirect or direct cytotoxic effect of BCG in situ remains unclear.
Bacillus Calmette-Gue ´rin-internalising urothelial cells and
the initiation/modulation of the immune response
Activation of the host immune system has been considered an
exclusive characteristic of professional antigen-presenting cells
(APCs), like dendritic cells and macrophages. New insights
support a role for the interaction of (airway)epithelial cells and
bacteria in the initiation of the immunological cascade (Levine,
1995; Neyrolles et al, 2001). Bacillus Calmette-Gue ´rin-treated
urothelial tumour cells are now considered as active participants in
the cytokine-mediated initiation and/or regulation of the early
immune response (Alexandroff et al, 1999).
The initial immune response to BCG The local immune response
to bacteria, including live BCG, is complex, but the presentation of
bacterial antigens by APC to T-helper cells is the pivotal
interaction (Alexandroff et al, 1999). Derived from an extensive
series of papers, it appears that, after internalisation and
processing by professional APC, processed BCG antigen(s) become
associated with MHC class II molecules (Figure 1D). The antigen–
MHC class II complex is expressed at the cell surface to be
recognised by CD4
þ T-helper lymphocytes via the T-cell receptor
(TCR) molecule (Figure 1E). Along with this binding, the
interaction between the APC and CD4
þ T cell is only fully
accomplished by an additional series of costimulatory, but
essential, interacting molecules. Among others, binding of CD4
to MHC class II, lymphocyte function-associated antigen-3 (LFA-
3) to intercellular adhesion molecule-1 (ICAM-1) and CD28
(CD4
þ cell) to B7 enhances the conjugation of the cells and
promotes T-cell activation signals. Soluble cytokines, such as IL-2,
IL-6 and IFN-g, provide generation of APC and T cells and ‘fine-
tuning’.
Depending on many nonspecific factors, including antigen dose,
type of APC and the expression of the mentioned membrane-
bound costimulatory signals of the T-helper cells, a so-called Th1-
type, and to some degree a Th2-type, response develops during
BCG treatment. The Th1 or cell-mediated immune response
and the Th2 or humoral immune response are characterised by
the patterns of cytokines, secreted by the CD4
þ T-helper
cells following antigen-specific stimulation. In mouse models, the
Th1 response is primarily characterised by IL-2, IL-12, IFN-g and
TNF-b, and the Th2 response by IL-4, IL-5, IL-6 and IL-10. The
recognition that this description of two types of responses reflects
the human immune response and that they are regulated in a
reciprocal fashion, critically regulated by the cytokines, represent a
major advance in the field of antitumour cytotoxicity mechanisms.
Knowledge concerning the APC–T-helper cell interaction and
development of Th1 and Th2 responses has been used to study the
BCG-induced role of the urothelium in antigen presentation and
initiation of the immune response.
Uroepithelial tumour cells and antigen-presenting properties Im-
munocompetence of the host is essential for BCG therapy.
Dendritic cells, macrophages and CD4þ T lymphocytes play a
crucial role in the antitumour effect. In addition, evidence exists
for an important role of epithelial, TCC cancer cells. Mouse
bladder tumour cells present BCG antigen to CD4
þ T cells, via
MHC class II molecules (Lattime et al, 1992). The initial
observations were extended for another murine cell line and a







































































Figure 1 Simplified scheme of the supposed mechanism of action of
BCG in tumour cell eradication. After its instillation in the bladder (A), BCG
(B) accumulates near the bladder wall, followed by adherence and passage
through the GAG layer of the bladder wall (C). Bacillus Calmette-Gue ´rin is
internalised and processed by professional antigen-presenting cells (APCs)
and (high-grade) tumour cells (D), and BCG antigens are presented to
CD4
þ T cells (E). Depending on various conditions, this results in the local
synthesis of a particular set of cytokines, known as the Th1-type or cell-
mediated immune response (F, G). The Th1 cytokine profile enables
recruitment and maturation of cytotoxic effector cells. No definite
statements can be made yet about the actual effector cell(s), but a key
role for NK cells in tumour cell killing has been proposed (H).
BCG therapy for bladder cancer
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ICAM-1 and B7-1 was observed. The antigen presentation factors
are enhanced in high-grade TCC cell lines only (Figure 1D) (Ikeda
et al, 2002). Quantitative immunohistochemistry has confirmed
the in vitro findings. Serial bladder biopsies and urinary cytospins,
taken before and after BCG therapy, revealed an upregulation of
MHC class II and ICAM-1 expression of urothelial tumour cells
(Jackson et al, 1994).
Interestingly and likely of uttermost importance, recently non-
MHC-encoded, CD1-restricted presentation of (glyco)lipid anti-
gens has been recognised (Maksymowych and Kane, 2000).
Although for BCG no data are available yet, CD4
þ CD1-restricted
T cells were observed in patients suffering from Mycobacterium
leprae (Sieling et al, 2000). These cells produce IFN-g, but not IL-4.
Bacillus Calmette-Gue ´rin therapy-related research has revealed an
increased CD1 expression of TCC cell lines in the presence of live
BCG (Ikeda et al, 2002) and a virtual absence of urinary IL-4
during BCG treatment (Nadler et al, 2003). Accordingly, it is
tempting to hypothesise that CD1-facilitated BCG antigen pre-
sentation contributes to the development of BCG immunity.
In summary, epithelial TCC cells gain the phenotypical
characteristics and functioning of APCs in the presence of BCG.
These functions strongly suggest that the BCG–high-grade tumour
cell interaction acts in cohort with the BCG–professional APC
interaction. Clinical observations seem to confirm this conclusion,
since BCG therapy seems to exert a better antitumour effect in
high-grade bladder cancer (Table 1).
Secretion of cytokines by urothelial tumour cells
Multiple studies have reported on cytokine production as a result
of BCG therapy. Following intravesical BCG instillations, there is
an increase in the urinary level of several cytokines, such as IL-1,
IL-2, IL-6, IL-8, IL-12, IL-18, TNF-a and IFN-g. Undoubtedly, the
major cell sources are the immunocompetent cells, but urothelial
cells contribute to a significant degree. In vitro studies with human
TCC cells revealed a BCG-induced upregulation of the cytokines
IL-6, IL-8, IL-10, GM-CSF, TNF-a and IFN-a, but not IFN-g, IL-2,
IL-4 and IL-12 (Figure 1F and G) (Boer de et al, 1997; Bevers et al,
1998). Of all cytokines produced by TCC cell lines, the cytokines
IL-6 and IL-8 are highly prominent and their role will be discussed
here in some detail.
Interleukin-6 Within the challenged immune system, several cell
types including APC produce IL-6. This multifunctional cytokine is
critically involved in the acute phase response, T-cell proliferation,
B-cell maturation, macrophage maturation and cytotoxic T-cell
differentiation. In combination with IL-1, IL-2 and IFN-g, IL-6
induces expression of the IL-2 receptor (IL-2R), thus participating
in the activation of resting T cells (Lauta, 2003). Furthermore, Il-6
seems to contribute to MHC-nonrestricted cytotoxic activity by
inducing natural killer (NK) cell proliferation. Nowadays, NK cells
are considered as essential, cytotoxic effector cells during BCG
therapy (Figure 1H) (Brandau et al, 2001).
High-grade TCC cell lines show a high constitutive and BCG-
induced production of IL-6. However, the importance of IL-6
produced by bladder cancer cells in the BCG-induced immune
response remains to be established. In vitro studies revealed that
IL-6 mRNA upregulation and IL-6 production depend on BCG
dose, incubation period, BCG internalisation and TCC cell grade
(Bevers et al, 1998). Interleukin-6 production requires a minimal
BCG exposure time of 0.5–1h, which is in accordance with clinical
practice.
Interleukin-6 is considered a major source of early Th1/Th2
control during CD4
þ T-cell activation as it attributes to the
promotion of the Th2 response and simultaneously inhibition of
Th1 polarisation (Figure 1G). Interleukin-6 activates the produc-
tion of IL-4 by CD4
þ T cells and their differentiation into Th2
effector cells. Moreover, it inhibits Th1 differentiation by
interference with IFN-g signalling and the development of Th1
cells (Diehl and Rincon, 2002). The abundant IL-6 response during
BCG therapy and virtually the absence of urinary IL-4 seem to be
however in conflict with the recognition that the presence of BCG
primarily induces a Th1 response. The absence of IL-4 and a high
production of IFN-g may prevent or contradict the Th2-promoting
effect of IL-6. Moreover, this finding suggests an important role of
the CD1-restricted presentation of (glyco)lipid antigens of live
BCG , since CD4
þ CD1-restricted T cells produce IFN-g but not
IL-4 (Sieling et al, 2000; Ikeda et al, 2002).
Interleukin-8 Interleukin-8 is a proinflammatory cytokine with
strong chemotactic properties, attracting T lymphocytes and
neutrophils. Interleukin-8 is induced rapidly, already after the
first instillation, during BCG therapy (Boer de et al, 1997).
Dendritic cells, macrophages and a number of other cells,
including TCC cell lines, produce IL-8. The early urinary IL-8
production in vivo may indicate the significance of an interaction
of BCG bacilli with (residual) bladder cancer cells in the initiation
of the host immune response.
Cell-mediated antitumour effects: the effector cells
The final step in the eradication of tumour cells consists of
mobilisation and activation of cytotoxic effector cells (Figure 1H).
Several in vitro studies show evidence for several nonspecific cytolytic
cells like NK cells, BCG-activated killer cells (BAKs), macrophage-
activated killer cells (MAKs), lymphokine-activated killer cells (LAKs)
and cytotoxic T lymphocytes (Kawashima et al, 2003).
A key role is supposed for NK cells (Brandau et al,2 0 0 1 ) .N K
cells, a special population of mononuclear cells, recognise ‘self’-
peptides presented by MHC class I molecules on the surface of cells.
A cell not displaying these peptides in a correct way is attacked and
killed by NK cells (Ka ¨rre, 1995). In untreated bladder cancer
patients, a loss or alteration of MHC class I expression is seen in
tumour cells (Saint et al, 2001). Bacillus Calmette-Gue ´rin-infected
cells present BCG glycoprotein and lipoprotein antigens on their
MHC class I molecule (Neyrolles et al,2 0 0 1 ) .T h i sm a yb eat r i g g e r
for NK cells to attack BCG-infected urothelial tumour cells. Bacillus
Calmette-Gue ´rin therapy in the murine model, using NK cell-
deficient mice, is ineffective (Brandau et al,2 0 0 1 ) .H o w e v e r ,i n
studies regarding the presence of NK cells after BCG therapy,
relatively few NK cells were seen 3 weeks after the last instillation of
a6 - w e e kc o u r s e( L a t t i m eet al, 1992; Saint et al,2 0 0 1 ) .I tw o u l db e
interesting to know if NK cells are more abundant earlier, during the
BCG course. Strong direct evidence for NK cell or other effector
cell(s) is still lacking. The recent acknowledgement of effector cells
that recognise mycobacterial (glyco)lipid antigens through non-
polymorphic MHC molecules, such as CD1, may provide new
insights into the true nature of the cytolytic effector cells involved in
tumour cell eradication during BCG treatment (Maksymowych and
Kane, 2000; Kawashima et al,2 0 0 3 ) .
SUMMARY AND CONCLUSIONS
Current insight of the mode of action of BCG, ranging from its
introduction into the bladder to killing of residual tumour cells,
has revealed a complex sequence of processes. Bacillus Calmette-
Gue ´rin accumulates near, and adheres to, the bladder wall. After
passage through the GAG layer, BCG is internalised and processed
by professional APC and tumour cells. The modified gene
expression of these cells accumulates in the secretion of particular
cytokines and presentation of BCG antigens. Bacillus Calmette-
Gue ´rin antigens are presented via MHC class II molecules to CD4
þ
T cells and via MHC class I molecules to CD8
þ T cells. Lipid and
glycolipid BCG antigens can be presented to CD4
þ and CD8
þ T
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of chemokines, such as IL-8, secreted partly by BCG-internalised
tumour cells, contributes to the local activation of the immune
system. Consequently, activated leucocytes and mononuclear cells
invade the bladder wall. These developments provide the condition
for a Th1 response, associated with particular cytokines (IFN-g, IL-
2, IL-12 and TNF-b). This cytokines profile promotes delayed-type
hypersensitivity response, cytotoxic cell response, and macrophage
activation or cellular immune inflammatory reaction. Depending
on bacterial and host components, an upregulation of the Th2
response, associated with cytokines IL-6 and IL-10, may occur to
some degree and adversely affect the functioning of the Th1
response. The Th1 cytokine profile enables recruitment and
maturation of cytotoxic effector cells.
No definite statements can be made yet about the actual effector
cell(s), but a crucial, cytotoxic role of NK cells has been proposed.
In addition, some of the cytokines, and BCG itself, may exhibit a
direct cytotoxic effect on tumour cells.
In 28 years of major research efforts, understanding of the mode
of action underlying BCG therapy for bladder carcinoma is
obviously much improved. Yet the jigsaw is not complete and
many details wait unraveling. However, if successful, the reward
might be a better, evidence-based BCG immunotherapy with
optimal clinical efficacy and minimal occurrence of side effects in
the form of an optimal BCG dose and treatment schedule,
genetically engineered BCG, or particular antigenic molecule(s)
that trigger immunological antitumour activity in a well-controlled
manner.
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